Clinical Trial Update: Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating maintenance durvalumab and olaparib after first-line therapy in HRD-positive extensive-disease small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Imfinzi (durvalumab) (durvalumab)
• Lynparza (Olaparib) (Olaparib)

Snippet

Sponsor: University of Cologne | Conditions: Small Cell Lung Carcinoma | Phase 2 | Status: ENROLLING_BY_INVITATION